SEKISUI XENOTECH

Consulting

Sekisui XenoTech Consulting provides innovative approaches for successful drug development.

When assessing your compound development strategy, it is essential to understand where you are going and how you are going to get there. Whether it is explaining results from a study to plan your next move, or guidance about the FDA's perspective, Sekiui XenoTech's DDI and drug metabolism consulting experts can provide the strategy behind the science.

Worldwide Experience & Expertise

Our consulting team has a strong history of experience and unsurpassed expertise regarding metabolism-related research. The Sekisui XenoTech consulting team was mentored by one of the world's leading experts on hepatic drug metabolism and toxicity, Dr. Andrew Parkinson*. Under his guidance, Sekisui XenoTech consulting developed a strong reputation for expertise and is frequently asked to consult with companies worldwide to help discover new and innovative approaches towards successful compound development. Let our team of experts move your drug development process forward with their extensive knowledge and industry experience.

Sekisui XenoTech's Vice President of Scientific Consulting, Dr. Brian Ogilvie, currently serves as the head of consulting services. Brian obtained his Ph.D. in toxicology from the University of Kansas Medical Center and B.A. in molecular biology from William Jewell College. He joined XenoTech in 1997. Brian is an author or coauthor on over 50 scientific posters, peer-reviewed publications or book chapters on the topics of drug metabolism, transport and drug-drug interactions, and has represented the company as an invited speaker at various drug metabolism conferences.

**Dr. Andrew Parkinson now serves as an independent consultant and is no longer affiliated with XenoTech.*

Innovative Solutions

Sekisui XenoTech Consulting can help navigate your compound development efforts with the following services:

- Structural alert review/prediction for metabolism and toxicity study optimization
- Prioritization of *in vitro* services based on data generated from previous studies
- Comprehensive review of all study-related data conducted at Sekisui XenoTech
- Recommend additional studies necessary to satisfy an IND/NDA submission
- Provide advice on the interpretation of pre-clinical ADME-Tox data and its extrapolation to the clinical setting, with special emphasis on *in vitro/in vivo* extrapolation (IVIVE) and an evaluation of the victim and perpetrator potential of a drug candidate
- Prepare expert opinion papers on ADME-Tox issues
- Review or prepare material for Investigator's brochures
- Prepare responses to questions from the FDA and other regulatory agencies
- Attend FDA Advisory Board meetings and FDA hearings in a consulting capacity
- Deliver lectures on special topics, including basic courses on drug metabolism

Invest your time and money wisely, let XenoTech Consulting guide you in the right direction for all of your drug development needs!

For more information, please contact us at **913.438.7450**
or email us at **info@xenotechllc.com**